REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Immunoglobulin, Antiserum, Antibody, Or Antibody Fragment, Except Conjugate Or Complex Of The Same With Nonimmunoglobulin Material > Monoclonal Antibody Or Fragment Thereof (i.e., Produced By Any Cloning Technology) > Binds Enzyme Binds EnzymeBinds Enzyme patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.07/26/07 - 20070172484 - Immunizing compostion and method for inducing an immune response against the beta-secretase cleavage site of amyloid precursor protein The present invention is directed to an immunizing composition containing an antigenic product such as a multiple antigen peptide system (MAPS) or a filamentous bacteriophage displaying an AβPP epitope spanning the β-secretase cleavage site of AβPP and a method for inducing an immune response against the β-secretase cleavage site of ... 07/26/07 - 20070172483 - Methods for treating conditions associated with masp-2 dependent complement activation In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 ... 07/26/07 - 20070172482 - Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins A method of producing a metalloprotein inhibitor, the method comprising generating antibodies directed at a composition including a metal ion-bound chelator, wherein the composition is selected having structural and electronic properties similar to a functional domain of the metalloprotein, thereby producing the metalloprotein inhibitor. ... 07/19/07 - 20070166311 - Monoclonal antibody The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. The ... 07/12/07 - 20070160616 - Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof Monoclonal antibodies directed against amyloid beta peptide and methods of using same for treatment and prevention of Alzheimer's disease and Down's syndrome are described. ... 07/12/07 - 20070160615 - Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease The subject invention provides methods of treating amyloidogenic diseases, comprising the administration of therapeutically effective amounts of a composition comprising a carrier and an agent that interferes with the interaction of CD40L and CD40R to an individual afflicted with an amyloidogenic disease. Also provided are methods and/or assay systems for ... 07/12/07 - 20070160614 - Human timp-1 antibodies Human antibodies that bind to TIMP-1 can be used as reagents to diagnose and treat disorders in which TIMP-1 is elevated, such as liver fibrosis, alcoholic liver disease, cardiac fibrosis, acute coronary syndrome, lupus nephritis, glomerulosclerotic renal disease, benign prostate hypertrophy, colon cancer, lung cancer, and idiopathic pulmonary fibrosis. ... 07/05/07 - 20070154482 - Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state Disclosed herein are methods for treating a vascular leak disorder, hypotension, or a procoagulant state using angiopoietin-2 (Ang-2) antagonist compounds. Also disclosed are methods for treating a vascular leak disorder associated with high dose IL-2 therapy using angiopoietin-2 antagonist compounds. Methods for diagnosing and monitoring vascular leak disorders, hypotension, or ... 06/28/07 - 20070148174 - Nuclease inhibitor cocktail Methods and compositions for inhibiting and/or inactivating nucleases by employing nuclease inhibitors are provided. The nuclease inhibitors comprise anti-nuclease antibodies and non-antibody nuclease inhibitors. The anti-nuclease antibodies of the present invention may be a polyclonal or monoclonal antibodies, and may be anti-ribonuclease antibodies, anti-deoxyribonuclease antibodies, or antibodies to non-specific nucleases. ... 06/28/07 - 20070148173 - Treatment of acute lung injury, fibrosis and metastasis with antagonists of alpha v beta 6 Methods and compositions comprising antagonists of αvβ6 are provided for the treatment of acute lung injury fibrosis. ... 06/21/07 - 20070141060 - Hmgb1 protein inhibitors for the regulation of smooth muscle cells and endothelial cells profileration The use of molecules that modulate the action of HMGB1 protein (or molecules having sequence homology) for the preparation of therapeutic agents for the treatment of diseases to related to endothelial and smooth muscle cells proliferation; said proliferation can be due to endothelium damage, caused by surgical operation and manipulation ... 06/21/07 - 20070141059 - Use of cathepsin s inhibitors for treating an immune response caused by administration of a small molecule therapeutic or biologic The present invention is directed to the use of Cathepsin S inhibitors in combination with a therapy that causes a deleterious immune response in patients receiving the therapy. ... 06/14/07 - 20070134247 - Prevention of brain inflammation as a result of induced autoimmune response A disease characterized by amyloid aggregation in a patient may be prevented or treated by causing antibodies against a peptide component of the amyloid deposit to come into contact with the aggregated or soluble amyloid. In order to decrease the risk of inflammation in such a method, the Fc receptors ... 06/07/07 - 20070128200 - Growth arrest specific gene 6 peptides, antibodies, compositions, methods and uses The present invention provides novel proteins and peptides from the receptor binding region of human Growth Arrest Specific Gene 6 (Gas6) and antibodies, including specified portions or variants, specific for at least one such Gas6 peptide or fragment thereof. The aforesaid peptides can be used to generate human, primate, rodent, ... 06/07/07 - 20070128199 - Dsp-3 dual-specificity phosphatase Compositions and methods are provided for the treatment of conditions associated with cell proliferation, cell differentiation and cell survival. In particular, the dual-specificity phosphatase DSP-3, and polypeptide variants thereof that stimulate dephosphorylation of DSP-3 substrates, are provided. The polypeptides may be used, for example, to identify antibodies and other agents ... 05/24/07 - 20070116705 - Novel pdes and uses thereof The present invention provides isolated full-length nucleic acid molecules encoding the novel PDE protein of the invention, and methods for uses thereof. The nucleic acid molecules of the invention also include peptide nucleic acids (PNA), and antisense molecules that react with the nucleic acid molecules of the invention. The invention ... 05/17/07 - 20070110752 - Fibroblast growth factor receptors and methods for their use Isolated fibroblast growth factor receptor 5 (FGFR5) polypeptides are provided, together with polynucleotides encoding such polypeptides. Also provided are modulators of FGFR5 gene expression and binding molecules that specifically bind to, and agonize or antagonize, FGFR5 polypeptide finction. Binding molecules include antibodies, and functional fragments thereof, as well as scFv ... 05/17/07 - 20070110751 - Compositions and methods for reducing infarct size Disclosed are compositions and methods for Disclosed are methods related to the use of Cdk2 inhibitors to reducing myocardial ischemic/reperfusion injury including but not limited to reduced infarct size. It is also disclosed that the same methods are equally appropriate for use in reducing injury following stroke including but not ... 05/17/07 - 20070110750 - Monoclonal antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence Methods for the production of monoclonal antibodies specific to conformational epitope(s) of a prefibrilar aggregate(s) which contribute to amyloid fibril formation in human or animal subjects who suffer from amyloid diseases (e.g. Alzheimer's Disease) and the hybridomas and monoclonal antibodies produced therefrom. Also, the use of such monoclonal antibodies in ... 05/10/07 - 20070104715 - Antibodies binding to a c-terminal fragment of apoliopoprotein e A human antibody fragment, which antibody or fragment: (i) binds to a polypeptide having the amino acid sequence shown in SEQ ID NO: 1 of the C-terminal domain of Apolipoprotein E (ApoE-CTD) or the amino acid sequence of a part thereof; and (ii) binds to human plaques. ... 05/10/07 - 20070104714 - Composition and method for the treatment of cancer and other physiologic conditins based on modulation of the ppar-gamma pathway and her-kinase axis Described herein are methods of using a NSAID and a HER-kinase axis inhibitor in the treatment of various conditions including cancer, and especially prostate, breast, lung, ovarian, brain and colon cancers, through regulation of PPARγ activity. In various embodiments, the NSAID and HER-kinase axis inhibitor may be included in a ... 04/12/07 - 20070081999 - Antithrombotic von willebrand factor (vwf) collagen bridging blockers The present invention clearly demonstrates that vWF-collagen interaction plays an important role in acute platelet-dependent arterial thrombus formation and that blockade of vWF-collagen interaction can induce complete abolition of thrombus formation in the injured and stenosed baboon femoral arteries. Accordingly, a blocker of vWF-collagen can be used as a compound ... 04/12/07 - 20070081998 - Anti-addl monoclonal antibody and use thereof The present invention relates to antibodies that differentially recognize multi-dimensional conformations of Aβ-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also ... 04/12/07 - 20070081997 - Diagnostics and therapeutics for diseases associated with kallikrein 9 (klk9) The invention provides a human KLK9 which is associated with the hematological diseases, cardiovascular diseases, neurological diseases, metabolic diseases, urological diseases, cancer disorders, inflammation disorders, dermatological diseases and gastroenterological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of hematological diseases, cardiovascular ... 04/05/07 - 20070077251 - Lipoprotein associated phospholipase a2, inhibitors thereof and use of the same in diagnosis and therapy The enzyme Lp-PLA2 in purified form, an isolated nucleic acid molecule encoding Lp-PLA2, the use of an inhibitor of the enzyme Lp-PLA2 in therapy and a method of screening compounds to identify those compounds. ... 04/05/07 - 20070077250 - Novel core 2 beta-1,6-n-acetylglycosaminyltransferase gene The invention provides novel core 2 β-1,6-N-acetylglycosaminyltransferase nucleic acids, and polypeptides encoded by the nucleic acids. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists, and methods for treating disorders associated with the enzyme. ... 03/29/07 - 20070071752 - Sphingosine kinase enzyme The present invention relates generally to novel protein molecules and to derivatives, analogues, chemical equivalents and mimetics thereof capable of modulating cellular activity and, in particular, modulating cellular activity via the modulation of signal transduction. More particularly, the present invention relates to human sphingosine kinase and to derivatives, analogues, chemical ... 03/29/07 - 20070071751 - Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof An isolated polynucleotide at least 60% homologous to SEQ ID NO: 1, 3, 5 or 18 encoding a SARP polypeptide; vectors comprising a polynucleotide sequence encoding at least 11 consecutive amino acids of αSARP polypeptide; a host cell transformed with an isolated polynucleotide or vector; antibodies specific for SARP and ... 03/29/07 - 20070071750 - Human antibody variants that specifically recognize the toxin cn2 from centruroides noxius scorpion venom The present invention is directed to recombinant human antibodies specific for Cn2 toxin from C. noxius scorpion venom. The antibodies are able to recognize the toxin and preferably neutralize it as well as the whole venom of C. noxius scorpion. This invention is also directed to a human non-immune phage ... 03/22/07 - 20070065445 - Novel cyclooxygenase variants and methods of use The invention relates to the isolation of novel cyclooxygenase type 1 (COX-1) variant enzymes. More specifically, the invention relates to the identification of cyclooxygenase transcripts harboring inton 1, or fragment thereof, of cyclooxygenase 1. The invention further relates to the diagnosis of aberrant cyclooxygenase type 1 variant gene or gene ... 03/22/07 - 20070065444 - Human monoclonal antibodies to activin receptor-like kinase-1 The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to the extracellular domain (ECD) of activin receptor-like kinase-1 (ALK-1) and that function to abrogate the ALK-1/TGF-beta-1/Smad1 signaling pathway. The invention also relates to heavy and light chain immunoglobulins derived from human anti-ALK-1 antibodies and ... 03/22/07 - 20070065443 - Fructoseamine 3 kinase and the formation of collagen and elastin The invention relates to the discovery that levels of collagen and elastin can be modulated by changing the flux through the Amadori Pathway and that copper containing compounds and complexes inhibit the enzyme fructoseamine-3-kinase. ... 03/15/07 - 20070059314 - Novel anti-angiogenic agent and its use in particular within the framework of the treatment of cancer The present invention relates to the use of a protein characterized in that it comprises or is constituted by the NOV protein, represented by the sequence SEQ ID NO: 2, or a fragment of this protein, providing that this fragment exhibits an angiogenesis-inhibiting activity, or any sequence derived from the ... 03/08/07 - 20070053913 - Diagnostics and therapeutics for diseases associated with g-protein coupled receptor adipor2 (adipor2) The invention provides a human AdipoR2 which is associated with the cardiovascular diseases, dermatological diseases, gastroenterological diseases, cancer, hematological diseases, respiratory diseases, inflammation, neurological diseases, urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, dermatological diseases, gastroenterological diseases, ... 03/08/07 - 20070053912 - Compounds for neutralizing the effects of secreted pla2iia A compound comprising at least a structural entity which binds secretory phospholipase A2 IIA (sPLA2 IIA) or parts of it and more preferably human sPLA2 IIA and which a.) blocks at least one or more sPLA2 IIA function on cell surfaces or in a solution, preferably blood or other body ... 03/08/07 - 20070053911 - Diagnostics and therapeutics for diseases associated with g-protein coupled proteinase activated receptor 2 (par2) The invention provides a human PAR2 which is associated with the cardiovascular disorders, gastrointestinal and liver diseases, neurological disorders, urological disorders, hematological diseases and respiratory diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular disorders, gastrointestinal and liver diseases, neurological ... 03/08/07 - 20070053910 - Modulation of s6 kinase activity for the treatment of obesity This invention provides screening methods for agents effective in treating obesity through specific inhibition of S6 kinase 1 activity. Also provided are methods of treating obesity by administering an effective amount of an inhibitor specific for S6 kinase 1. ... 03/01/07 - 20070048322 - Human aminoacyl-trna synthetase polypeptides useful for the regulation of angiogenesis Nucleic acids encoding tRNA synthetase polypeptides useful for regulating angiogenesis are disclosed. Methods of making and using such nucleic acids are also disclosed. ... 03/01/07 - 20070048321 - Method for the treatment of fibrosis Disclosed is a method of treating fibrosis in a human or animal subject. The method comprises administering to the subject an effective amount of an antibody to an integrin or fragment thereof. ... 03/01/07 - 20070048320 - Method for indentifying modulators of ppil2 useful for treating alzheimer's disease Methods for identifying modulators of PPIL2 are described. The methods are particularly useful for identifying analytes that antagonize PPIL2's effect on processing of amyloid precursor protein to Aβ peptide and thus useful for identifying analytes that can be used for treating Alzheimer disease. ... 02/22/07 - 20070041979 - Proteolysis resistant antibody preparations Antibody preparations with substantially homogeneous and unsialylated glycoforms, such as G0 and G2, are prepared by enzymatic treatment, expression under certain conditions, use of particular host cells, and contact with serum. These antibody preparations resist cleavage by proteases, such as papain, ficin, bromolein, pepsin, a matrix metalloproteinase, such as MMP-7, ... 02/22/07 - 20070041978 - Bispecific antibody substituting for functional proteins The present inventors succeeded in constructing bispecific antibodies, which bind to both the blood coagulation factor IX/activated blood coagulation factor IX and blood coagulation factor X, and functionally substitute for blood coagulation factor VIII/activated blood coagulation factor VIII which enhances the enzymatic reaction. ... 02/22/07 - 20070041977 - Single-chain antibody acting against 37 kda/67 kda laminin receptor as tools for the diagnosis and therapy of prion diseases and cancer, production and use thereof Single-chain antibodies are described which specifically recognize both the 37 kDa precursor form of the laminin receptor (37 kDa LRP) and the 67 kDa high-affinity form of the laminin receptor (67 kDa LR), and pharmaceutical and diagnostic compositions which contain these single-chain antibodies. ... 02/15/07 - 20070036794 - Agonist anti-trk-c monoclonal antibodies The invention concerns agonist anti-trkC monoclonal antibodies which mimic certain biological activities of NT-3, the native ligand of trkC. The invention further concerns the use of such antibodies in the prevention and/or treatment of cellular degeneration, including nerve cell damage associated with acute nervous cell system injury and chronic neurodegenerative ... 02/15/07 - 20070036793 - Methods for use of an lkb1/strad7mo25 complex A method for identifying a compound for use in modulating, for example promoting, the activation or phosphorylation of AMPK (AMP-activated protein kinase) or AMPK subfamily member in a cell, the method comprising the steps of (1) determining whether a test compound modulates, for example promotes, the protein kinase activity of ... 02/08/07 - 20070031422 - Selection of cells expressing heteromeric polypeptides This invention is in the general field of recombinant expression of polypeptides in animal cell culture. More particularly, the invention concerns improved selection in cells of recombinantly engineered vectors designed to express polypeptides. ... 02/08/07 - 20070031421 - Inhibitors targeting osteoclast-associated protein The present invention relates to a method of detecting metabolic bone disorders using a gene expressed at a high level in osteoclasts, a method of screening for a compound effective for treatment and/or prevention of metabolic bone disorders, and a pharmaceutical composition for treatment and/or prevention of metabolic bone disorders. ... 02/08/07 - 20070031420 - Masp-2, a complement-fixing enzyme, and uses for it The invention relates to the discovery and characterization of mannan binding lectin-associated serine protease-2 (MASP-2), a new serine protease that acts in the MBLectin complement fixation pathway. ... 02/08/07 - 20070031419 - Methods and compositions for treating diseases targeting cdcp1 Methods and compositions for detecting and treating a disease, particularly cancer, associated with differential expression of CDCP1 in disease cells compared to healthy cells. Also provided are antagonists or agonists of CDCP1, and methods for screening agents that modulate the CDCP1 level or activity in vivo or in vitro. ... 02/08/07 - 20070031418 - Methods for treating lower motor neuron diseases and compositions containing the same This invention provides methods for the treatment, prevention, and/or amelioration of symptoms relating to lower motor neuron diseases (such as spinal muscular atrophy). The methods comprise administration of an agonist anti-trkC antibody. Compositions and kits are also provided. ... 02/08/07 - 20070031417 - Dicer interacting proteins and uses therefor ABSTRACT Dicer (e.g., DCR-1) interactors are disclosed as are methods to positively or negatively modulate Dicer activity. Uses of Dicer interactors as drug targets are featured. Also featured are uses of Dicer interactors and modulators of same to modulate various Dicer functions in vitro, in cell cultures, and ... 02/08/07 - 20070031416 - Use of antibody The present invention intended to provide an agent for preventing/treating Alzheimer's disease. More specifically, the present invention provides an agent for preventing/treating Alzheimer's disease, etc., which comprises a monoclonal antibody specifically reacting with a partial peptide at the C-terminal region of a β-amyloid or its derivatives. ... 02/08/07 - 20070031415 - Regulation of interaction between rapl and rap1 A functional failure of Rap1 as a molecule that regulates integrin adhesion is believed to be related to pathology of inflammation, allergy, autoimmune diseases, cancer immunity, transplantation immunity, and the like that are immune diseases, and therefore elucidation of the mechanism of regulation of integrin adhesion by Rap1 leads to ... 01/25/07 - 20070020270 - Human serpin polypeptides This invention relates to Thypin, a new member of the human serpin polypeptide family, methods of making Thypin polypeptides and using these polypeptides to treat various medical disorders and to methods of screening for compounds that agonize or antagonize Thypin polypeptide activities. ... 01/25/07 - 20070020269 - Phosphokinase and the usage thereof The present invention relates to a novel phosphokinase, RX50 protein, polynucleotide encoding RX50 protein and the recombinant method of producing the same. RX50 protein can interact with p21 and cyclin D3, and inhibit the transcription of p53. Therefore, it can be used as a drug target for new drug selection. ... 01/11/07 - 20070009529 - Agents that dissolve arterial thrombi Agents that induce platelet fragmentation include an IgG antibody that reacts with platelet epitope GPIIIA49-66 on platelet membrane, recombinant AMANTS-18, phorbol 12-myristate 13-acetate (PMA) and A23817. ... 01/11/07 - 20070009528 - Antibodies to masp-2 The invention relates to antibodies to MASP-2 and functional equivalents thereof. In particular, the invention relates to MASP-2 antibodies capable of inhibiting the function of MASP-2. The invention furthermore discloses MASP-2 epitopes, wherein antibodies recognising said epitopes are in particularly useful for inhibiting MASP-2 activity. The invention also relates to ... 01/04/07 - 20070003554 - Variable heavy chain and variable light chain regions of antibodies to human platelet glycoprotein ib alpha The present invention is directed to a method of selecting a clone that binds to human platelet glycoprotein Ib alpha using a human variable heavy chain and variable light chain immunoglobulin library. The invention is further directed to isolated nucleic acid molecules encoding a variable heavy chain or variable light ... 01/04/07 - 20070003553 - Anticoagulant agents useful in treatment of thrombosis Chimeric, humanized and other IL-5 mAbs, derived from high affinity neutralizing mAbs, pharmaceutical compositions containing same, methods of treatment and diagnostics are provided. ... 01/04/07 - 20070003552 - Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with The invention relates to the field of biochemistry, molecular biology, structural biology and medicine. More in particular, the invention relates to cross-β structures and the biological role of these cross-β structures. ... 01/04/07 - 20070003551 - Immunoglobulin A recombinant human immunoglobulin exhibiting immuno-specificity for integrins is described. In addition, nucleotide and peptide sequences encoding the recombinant immunoglobulin are descrebed, and uses thereof. ... 12/28/06 - 20060292153 - Polypeptides, polynucleotides encoding same, antibodies thereagainst and methods of using same for diagnosing and treating cancer and skeletal disorders An isolated polypeptide is provided, comprising an amino acid sequence being at least 88% homologous to SEQ ID NO: 15 as determined by BlastP using default parameters, the isolated polypeptide being capable of promoting cell adhesion and/or cell homing. ... 12/28/06 - 20060292152 - Antibodies directed against amyloid-beta peptide and methods using same Antibodies directed to the C-terminal side of β-amyloid peptide and methods of using these antibodies for diagnosing and treatment of Alzheimer's disease and Aβ peptide associated diseases are described. ... 12/28/06 - 20060292151 - L-sign polymorphisms and methods involving use of same This invention concerns methods for determining whether an agent preferentially binds to at least one allelic variant of L-SIGN. The invention is also directed to agents that preferentially bind to at least one allelic variant of L-SIGN. The invention also provides methods and agents for treating and preventing disorders associated ... 12/28/06 - 20060292150 - Methods of using wisp antagonists Methods and compositions for use in blocking or inhibiting the activity(s) of WISP-1 polypeptide on chondrocytes are provided. WISP-1 antagonists include anti-WISP-1 antibodies, WISP-1 immunoadhesins and WISP-1 variants (and fusion proteins thereof) which inhibit or neutralize the effects of WISP-1 on mammalian chondrocytes. ... 12/28/06 - 20060292149 - Variable antibodies The present invention discloses inhibitory antibodies against Factor VIII with modified glycosylation, either by enzymatic deglycosylation or by site directed mutagenesis. Said antibodies with modified glycosylation have equal affinity for FVIII but show different inhibiting properties. The use of one or a mixture of said antibodies allow modulation of the ... 12/14/06 - 20060280745 - Prion inhibition The invention relates to the use of an agent such as an antibody capable of reacting with PrP in the prevention of prion replication in a subject, in the treatment or prevention of prion infection, in the treatment or prevention of neuropathology associated with prion infection or in the preparation ... 12/07/06 - 20060275300 - P450rai-2 (p450 cytochrome 26b), encoding nucleic acid molecules and methods and uses thereof The present invention provides a novel all-trans-RA inducible all-trans-RA metabolizing cytochrome P450, P450RAI-2, that is predominantly expressed in the brain, cerebellum in particular. It is also expressed in normal and tumour lung tissue and in breast cancer cells and may have a correlation with lung and breast cancer. Human P450RAI-2 ... 12/07/06 - 20060275299 - Use of protein tyrosine phosphatase inhibitors for prevention and/or treatment of cancer The invention relates to the use of a protein tyrosine phosphatase inhibitor, such as a cross-linker of a protein tyrosine phosphatase (PTP), in particular Sap-1, in the preparation of a medicament for treatment and/or prevention of cancer, and to methods of treating and/or preventing cancer using these inhibitors. ... 11/30/06 - 20060269552 - Heparanase activity neutralizing anti-heparanase monclonal antibody and other anti-heparanase antibodies Specific anti-heparanase antibodies which bind specifically to heparanase having sequence homology to human heparanase, which can be used to treat and diagnose conditions associated with heparanase catalytic activity, for purification of heparanase, and for drug development in heparanase associated conditions are disclosed. ... 11/23/06 - 20060263365 - Method of immunomodulation The present invention relates generally to a method for modulating the immuno-activity of an antigen-presenting cell and agents useful therefor. More particularly, the present invention relates to a method for preventing or down-regulating one or more functional activities of a dendritic cell. The present invention further provides antibodies and, in ... 11/02/06 - 20060246076 - Inducible nitric oxide synthase binds, s-nitrosylates, and activates cyclooxygenase-2 Cyclooxygenase (COX2) and inducible nitric oxide synthase (iNOS) are two major inflammatory mediators. Inducible NOS specifically binds to COX2 and S-nitrosylates it, enhancing COX2 catalytic activity. Selectively disrupting iNOS—COX2 binding prevents NO-mediated activation of COX2. The synergistic molecular interaction between two inflammatory systems permits assays for developing anti-inflammatory drugs. ... 11/02/06 - 20060246075 - Anti-amyloid antibodies, compositions, methods and uses The present invention relates to at least one novel anti-amyloid antibody, including isolated nucleic acids that encode at least one anti-amyloid antibody, amyloid, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices. ... 11/02/06 - 20060246074 - Use of alpha 1-antichymotrypsin polypeptides, or nucleic acids encoding them, in combination with alpha 1- antitrypsin polypeptides, or nucleic acids encoding them, for treatment and/or prevention of diabetes-associated and/or arterial poorly healing woun The invention relates to a use of alpha 1-antichymotrypsin (ACT) polypeptides, functional variants thereof and/or nucleic acids encoding them, or of a cell which is expressing an ACT polypeptide or a nucleic acid encoding it in combination with alpha-1-antitrypsin (AAT) polypeptides, functional variants thereof or nucleic acids encoding them, or ... 10/26/06 - 20060240019 - Antagonists of hmg1 for treating inflammatory conditions There is disclosed a pharmaceutical composition and method for treating sepsis, including septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount of a HMG1 antagonist. There is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock, comprising measuring ... 10/19/06 - 20060233805 - Antigen uptake receptor for candida albicans on dendritic cells Dendritic cells (DC) that express the type II C-type lectin DC-SIGN (CD209) are located in the submucosa of tissues, where they mediate HIV-1 entry. Interestingly, the pathogen Candidaalbicans, the major cause of hospital-acquired fungal infections, is found at similar sites. Here it is demonstrated that DC-SIGN is able to bind ... 10/12/06 - 20060228362 - Novel protease gene A neurolysin-like substance having an activity of degrading a synthetic substrate Mcc-Pro-Leu-Gly-Pro-D-Lys(DNP)—OH, diagnostic means and pharmaceutical compositions employing it. ... 10/12/06 - 20060228361 - Dicer interacting proteins and uses therefor Dicer (e.g., DCR-1) interactors are disclosed as are methods to positively or negatively modulate Dicer activity. Uses of Dicer interactors as drug targets are featured. Also featured are uses of Dicer interactors and modulators of same to modulate various Dicer functions in vitro, in cell cultures, and in vivo. ... 10/05/06 - 20060222648 - Kim-1 antagonists and use to modulate immune system The use of KIM-1 antagonists to inhibit signaling between a T cell and a second cell, e.g., an antigen-presenting cell, is disclosed. Such inhibition is useful for treatment of diseases including various autoimmune diseases and graft-versus-host disease. Also disclosed is the use of a KIM-1 antagonist to inhibit secretion of ... 10/05/06 - 20060222647 - Methods and compositions for modulating the activity of pde5 The present invention provides agents such as agonists, antibodies, antagonists or inhibitors to modulate the activity of PDE5 proteins. These compositions and methods are useful for the diagnosis or treatment of conditions associated with the presence, the deficiency, altered levels, or altered activity of PDE5 proteins. ... 09/28/06 - 20060216297 - Method and composition for reducing blood sugar levels or fat storage by targeting cathepsin Methods and compositions are provided for reducing blood sugar levels or fat storage of animals by targeting the gene and gene products of cathepsins, particularly cathepsins L, K, and S. The method comprises: administering to the animal an agent that reduces an in vivo level of cathepsin L activity such ... 09/21/06 - 20060210567 - Antibodies against pd-1 and uses therefor This disclosure provides antibodies and antigen-binding fragments that can act as agonists and/or antagonists of PD-1 (Programmed Death 1), thereby modulating immune responses in general, and those mediated by TcR and CD28, in particular. The disclosed compositions and methods may be used for example, in treating autoimmune diseases, inflammatory disorders, ... 08/17/06 - 20060182748 - Method of creating antivenom using emus A method for creating an antivenom for snake bites comprising obtaining the venom from at least one poisonous snake, obtaining an adult ratite bird, injecting the adult ratite bird with the venom in appropriate amounts at appropriate intervals such that the ratite bird develops antibodies to the venom, extracting blood ... 08/10/06 - 20060177448 - Inhibiting her2 shedding with matrix metalloprotease antagonists The present application describes using antagonists of matrix metalloproteases (MMPs), especially of MMP-15, for inhibiting HER2 shedding. ... 07/27/06 - 20060165698 - L-amino acid oxidase with cytotoxic activity from aplysia punctata The present invention relates to a cytotoxic polypeptide which is an L-amino acid oxidase isolated from the ink of the sea hare Aplysia punctata. ... 07/27/06 - 20060165697 - Medicinal agent and method for curing erectile dysfunction A medicament based on antibodies contains an activated form of ultra-low doses of monoclonal, polyclonal, or natural antibodies to endothelial nitric oxide synthase (NO synthase), the activated form being prepared by multiple consecutive dilutions and exposure to external factors, preferably according to the homeopathic technology. A method of treating erectile ... 07/13/06 - 20060153852 - Novel human jak2 kinase The present invention provides a polynucleotide (hjak2) which identifies and encodes a novel human Jak2 kinase (HJAK2) which was expressed in the placenta. The present invention also provides for antisense molecules and oligomers designed from the nucleotide sequence or its antisense. The invention further provides genetically engineered expression vectors and ... 07/13/06 - 20060153851 - Clasp proteins The present invention relates to a cell surface molecules, designated cadherin-like asymmetry proteins (“CLASPs”). In particular, it relates to CLASP-2 polynucleotides, polypeptides, fusion proteins, and antibodies. The invention also relates to methods of modulating an immune response by interfering with CLASP function. ... 07/06/06 - 20060147454 - Human serine protease and serpin polypeptides The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing ... 07/06/06 - 20060147453 - Methods and compositions for modulating and detecting wisp activity Methods and compositions for use in modulating the activity(s) of WISP-1 polypeptide are provided. WISP-1 antagonists include anti-WISP-1 antibodies, WISP-1 immunoadhesins and WISP-1 variants (and fusion proteins thereof) which inhibit or neutralize induction or secretion of HAS2, HA, CD44 or RHAMM by native human WISP-1 polypeptide in at least one ... 06/29/06 - 20060140954 - Novel human protein kinases and protein kinase-like enzymes The present invention relates to kinase polypeptides, nucleotide sequences encoding the kinase polypeptides, as well as various products and methods useful for the diagnosis and treatment of various kinase-related diseases and conditions. Through the use of a bioinformatics strategy, mammalian members of the PTK's and STK's have been identified and ... 06/29/06 - 20060140953 - Systems and methods for treating human inflammatory and proliferative diseases and wounds, with ucp and/or fas antibody or other inhibitor, optionally with a fatty acid metabolism inhibitor and/or a glucose metabolism inhibitor Systems and methods for treating inflammatory and proliferative diseases, and wounds, using as a pharmacon a UCP and/or Fas antibody or other inhibitor, or combination thereof, and a therapeutically acceptable amount of a fatty acid metabolism inhibitor and/or a therapeutically acceptable amount of a glucose metabolism inhibitor, optionally in combination ... 06/22/06 - 20060134115 - Method of screening for sensitivity to kinase inhibitor therapy Described herein are methods for treating cancer and other disease conditions in individuals who have either developed a resistance to conventional tyrosine kinase inhibitor (TKI) therapy or who are non-responsive ab initio to conventional TKI therapy. In various embodiments, the methods include administering to a patient a resistance-surmounting quantity of ... 06/22/06 - 20060134114 - Novel human kallikrein-like genes The invention relates to nucleic acid molecules, kallikrein-like proteins encoded by such nucleic acid molecules; and use of the proteins and nucleic acid molecules. ... 06/15/06 - 20060127402 - Pharmaceutical compositions and methods useful for modulating angiogenesis, inhibiting metastasis and tumor fibrosis, and assessing the malignancy of colon cancer tumors Methods and compositions suitable for modulating angiogenesis in a mammalian tissue are provided. Further provided are methods suitable for inhibiting metastasis and fibrosis in a mammalian tissue and for assessing the malignancy of colon cancer tumors. ... 06/08/06 - 20060121040 - Compositions and methods for treating neuroendocrine tumors Methods and pharmaceutical compostions for treating or suppressing symptoms of neuroendocrine (NE) tumors comprising inhibiting the activities of GSK-3β of the cancer cells. Also disclosed are pharmaceutical compositions for the methods. Preferably, the pharmaceutical composition comprises Li+, SB216763, SB415286, indirubins, Paullones, Hymenialdisine, Azakenpaullone, Thienyl and phenyl α-halomethyl ketones, CHR 99021, ... 06/08/06 - 20060121039 - Use of agents that prevent the generation of amyloid-like proteins and/or drusen, and/or use of agents that promote sequestration and/or degradation of, and/or prevent the neurotoxic effects of such proteins in the treatment of macular degeneration The present invention provides compositions and methods for treating age-related macular degeneration (AMD). More specifically, the methods of the invention target amyloid proteins and drusen that tend to accumulate in the eyes of those patients suffering from AMD. AMD is treated in the methods of the invention by providing agents ... 06/08/06 - 20060121038 - Prevention and treatment of amyloidogenic disease The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit. The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease. ... 06/01/06 - 20060115480 - Disease treatment via antimicrobial peptide inhibitors A method of treating a disease in a subject in need thereof is disclosed. The method comprises providing to the subject a therapeutically effective amount of a compound being capable of decreasing an activity and/or level of an antimicrobial peptide (AMP) and/or AMP-like molecule, thereby treating the disease in the ... 06/01/06 - 20060115479 - Nucleic acids coding for adhesion factor of group b streptococcus, adhesion factors of group b streptococcus and further uses thereof The present invention is related to nucleic acids coding for adhesion factors of group B streptococcus, adhesion factors of group B streptococcus and uses thereof. More particularly, the present invention is related to a polypeptide being such adhesion factors and comprising an amino acid sequence, whereby the amino acid sequence ... 05/25/06 - 20060110391 - Compositions and methods for the treatment of body weight disorders, including obesity The invention provides isolated nucleic acids molecules, designated MKP nucleic acid molecules, which encode novel MAP kinase phosphatase family members, and their use in metabolic disorders. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing MKP nucleic acid molecules, host cells into which the expression vectors have ... 05/25/06 - 20060110390 - Inhibition of ku as a treatment for cardiovascular diseases The present invention provides for methods of treating and preventing cardiovascular diseases, in particular pathological cardiac hypertrophy and chronic heart failure, by applying an inhibitor of Ku. The present invention also provides for methods of screening to find inhibitors of Ku and inhibitors of cardiac hypertrophy and heart failure. ... 05/18/06 - 20060104979 - Mt-sp1 polynucleotides and polypeptides This invention provides a novel membrane-type serine protease (designated MT-SP1) elevated expression of which is associated with cancer. In one embodiment, this invention provides a method obtaining a prognosis or of detecting or staging a cancer in an organism. The method involves providing a biological sample from the organism and ... 05/18/06 - 20060104978 - Methods and compositions for pdgf-c activation and inhibition Methods for inhibiting angiogenesis comprising administering tissue-plasminogen activator (tPA) inhibitors, and pharmaceutical compositions suitable for the methods comprising the tPA inhibitors. Also provided are methods for stimulating angiogenesis comprising administering tPA to a patient in need thereof, and pharmaceutical compositions comprising an effective amount of tPA for the methods of ... 04/27/06 - 20060088535 - Method for enhancing long-term memory in a subject and uses thereof The present invention provides for a method to enhance long-term memory in a subject whose cAMP-responsive gene expression is repressed due to binding of a cAMP-response-element-binding-protein-2 to a protein or a DNA associated with cAMP-responsive gene expression, or both, which comprises administering to the subject a compound capable of interfering ... 04/27/06 - 20060088534 - Human anti-factor ix/ixa antibodies The invention provides for the isolation, identification, synthesis, expression and purification of antibodies reactive with factor IX (FIX)/factor IXa (IXa). In particular aspects, the invention provides human antibodies reactive with the human FIX Gla domain. The invention further provides compositions especially pharmaceutical compositions, articles of manufacture, and methods of inhibiting ... 04/13/06 - 20060078560 - Method of inducing apoptosis and inhibiting cardiolipin synthesis The present invention provides a method for inducing apoptosis within a cell by exposing the cell to an inhibitor of cardiolipin synthesis under conditions sufficient to induce apoptosis within the cell. The method can be used to investigate or treat disorders such as cancer, obesity, and cardiovascular disorders. The invention ... 04/06/06 - 20060073149 - Rapid improvement of cognition in condition related to abeta The present invention is a method for effecting rapid improvement in cognition in subjects suffering from conditions or diseases related to the Aβ peptide, including Alzheimer's disease, Down's syndrome, cerebral amyloid angiopathy, mild cognitive impairment, and the like. The method comprises administering anti-Aβ antibodies to the subject, especially antibodies having ... 03/30/06 - 20060067938 - Methods for the treatment of osteoarthritis and compositions thereof The invention discloses PI3K, PKB, IL-1, and OSM as suitable targets for the development of new therapeutics to treat, prevent or ameliorate osteoarthritis (OA). The invention relates to methods to treat, prevent or ameliorate OA and pharmaceutical compositions therefor comprising substances with inhibitory effects on PI3K and/or PKB enzyme activity ... 03/23/06 - 20060062792 - Novel human p53 splice variant displaying differential transcriptional activity Novel human p53 splice variant displaying differential transcriptional activity Described is a nucleic acid molecule encoding a p53 variant characterized in that it is capable of transactivating the p21- and 14-3-3σ-promoter but not the mdm2-, bax- and PIG3-promoter. Preferably, in said p53 variant exon 7, exon 8 and/or exon 9 ... 03/23/06 - 20060062791 - I kappa b kinase complex as a target for the treatment of huntington's disease The present invention provides methods and compositions for protecting cells from the toxicity of mutant huntingtin (Htt) protein and for treatment of Huntington's disease (HD). The methods generally involve administering to cells or a patient an effective amount of an IKK inhibitor. In addition, methods are provided for identifying therapeutics ... 03/23/06 - 20060062790 - Akt3 inhibitors Inhibitors of human Akt3, including antisense oligonucleotides, methods, and compositions specific for human Akt3, are provided. Methods of using the compositions for modulating Akt3 expression and for regulating cell growth, particularly tumor cell growth, are also provided. ... 02/23/06 - 20060039913 - Anti-mcp-1 antibodies, compositions, methods and uses The present invention relates to at least one novel anti-MCP-1 antibodies, including isolated nucleic acids that encode at least one anti-MCP-1 antibody, MCP-1, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices. ... 02/23/06 - 20060039912 - Antibodies to adipose tissues A non-therapeutic method of producing antibodies that bind adipose tissues in a target animal in need of the antibodies for modulating the content of adipose tissues in the target animal, the method comprising the steps of (a) preparing an antigen from the adipose tissues of a source animal, (b) administering ... 02/16/06 - 20060034848 - Methods and compositions for treating alzheimer's disease The present invention relates to the treatment, diagnosis, and prophylactic prevention of Alzheimer's disease. More specifically, the present invention relates to methods and compositions for reducing or preventing the interaction of β-secretase (BACE) with low density lipoprotein receptor related protein (LRP). ... 02/16/06 - 20060034847 - Methods of treating a subject for a condition Methods are provided for treating a subject for at least one condition that includes inflammation, a blood clotting condition and autonomic nervous system dysfunction such as adrenergia, e.g., simultaneously. Also provided are kits for use in practicing the subject methods. ... 02/02/06 - 20060024313 - Agents that disrupt dimer formation in dpp-iv family of prolyl dipeptidases The present invention relates to the finding that C-terminal loop and propeller loop and regions thereof of the DPP-IV family of prolyl dipeptidases play an important role in dimer formation. The present invention further provides purified polypeptides comprising an amino acid sequence that mimics conserved amino acids in at least ... 02/02/06 - 20060024312 - Methods for enhancing learning and memory Methods of maintaining or enhancing memory or learning in a mammal by activating the receptor tyrosine kinase muscle-specific kinase (MuSK) in the brain are disclosed. Also disclosed are methods of treating a disease or condition associated with memory loss or a neurological impairment by administering an effective amount of a ... 02/02/06 - 20060024311 - Anti-viral activity of an anti-thymidine kinase monoclonal antibody Monoclonal antibodies to thymidine kinase 1 are disclosed which are useful in methods of detecting, diagnosing, and treating viral infection. ... 01/12/06 - 20060008458 - Prevention of brain inflammation as a result of induced autoimmune response A disease characterized by amyloid aggregation in a patient may be prevented or treated by causing antibodies against a peptide component of the amyloid deposit to come into contact with the aggregated or soluble amyloid. In order to decrease the risk of inflammation in such a method, the Fc receptors ... 01/05/06 - 20060002938 - Methods of detecting the inhibition of fibrocyte formation and methods and compositions for enhancing fibrocyte formation The present invention relates to the ability of SAP to suppress the differentiation of monocytes into fibrocytes. It also relates to the ability of IL-4 and IL-3 to enhance the differentiation of monocytes into fibrocytes. Methods and compositions for binding SAP, decreasing SAP levels and suppressing SAP activity are provided. ... 01/05/06 - 20060002937 - Methods for treating conditions associated with masp-2 dependent complement activation In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 ... 01/05/06 - 20060002936 - Method of modulating platelet activation The present invention relates to a method of treating a disease or condition mediated by platelet activation comprising supplying a therapeutically effective amount of an ERP5 inhibitor to a patient in need thereof, so as to reduce the effects of platelet activation in said patient. ... 12/29/05 - 20050287145 - Compositions and methods for producing vascular occlusion The present invention relates generally to methods and compositions for targeting, delivering, and activating platelet-dependent vascular occlusion agents. In particular, antibodies carrying platelet binding agents are targeted to hyperplastic cells or tissues, such as the vasculature of solid tumor masses; the platelet binding agent then binds and activates platelets, which ... 12/29/05 - 20050287144 - Derivatives of the il-2 receptor gamma chain, their production and use This invention relates to the use of the IL-2 common gamma chain (cγc) and related molecules for the modulation of signal activities controlled by NIK, and some new such molecules ... 12/22/05 - 20050281826 - Therapeutic agent for inos generating illness cross-references to related applications A therapeutic agent which removes or neutralizes iNOS in the blood of a mammalian subject. The agent may be in the form of an anti-iNOS monoclonal antibody or an iNOS binding entity. ... 12/22/05 - 20050281825 - Cell proliferation inhibitor containing anti-pept antibody The present inventors extensively studied and found that an antibody binding to PepT has cytotoxic activity and inhibits cell growth. These results suggest that an antibody binding to PepT, particularly an antibody having a cytotoxic activity, can be used as a cell growth inhibitor, for example, in treating and preventing ... 12/15/05 - 20050276809 - Function of autophagy genes in cell death The present invention relates to a new molecular pathway in which activation of the receptor-interacting protein (RIP, a serine-threonine kinase) and Jun N-terminal kinase induce cell death with the morphology of autophagy. Further, autophagic death is induced by caspase 8 inhibition and expression of the mammalian genes ATG7 and beclin. ... 12/08/05 - 20050271668 - Janus family kinases and identification of immune modulators An isolated polynucleotide encodes JAK-3 protein. JAK-3 protein is a protein tyrosine kinase having a molecular weight of approximately 125 kDa which has tandem non-identical catalytic domains, lacks SH2 or SH3 domains, and is expressed in NK cells and stimulated or transformed T cells, but not in resting T cells. ... 12/08/05 - 20050271667 - Identification of a novel endothelial-derived gene eg-1 This invention provides a novel gene whose expression is upregulated during angiogenesis and/or tumorigenesis. Designated herein as EG-1, the gene provides a good target for modulators of angiogenesis and/or tumorigenesis. In addition, methods of inhibiting EG-1 and thereby inhibiting angiogenesis and metastasis are provided. ... 12/08/05 - 20050271666 - Regulation of human protein phosphatase iic-like enzyme Reagents which regulate human protein phosphatase IIC-like enzyme-like enzyme activity and reagents which bind to human protein phosphatase IIC-like enzyme-like enzyme gene products can be used, inter alia, to treat disorders associated with an increase in apoptosis, including AIDS and other infectious or genetic immunodeficiencies, neurodegenerative diseases, myelodysplasia, ischemic injuries, ... 11/17/05 - 20050255114 - Methods and diagnosis for the treatment of preeclampsia Provided by the present invention are methods for treating and diagnosing preeclampsia, as well as kits for use in diagnosing patients with a higher risk of preeclampsia. ... 11/03/05 - 20050244415 - Pharmaceutical composition and method for activating macrophage using the same A pharmaceutical composition is produced by obtaining an antibody which specifically recognizes an extracellular domain of SIRPβ and formulating the antibody with a pharmaceutical acceptable carrier. The patient suffering from infectious disease or cancer is treated by administering the pharmaceutical composition to activate macrophages. ... 10/20/05 - 20050232924 - Antibodies and/or conjugates thereof which bind to the amino terminal fragment of urokinase, compositions and uses thereof Antibodies and/or conjugates thereof which bind to the amino terminal fragment of urokinase, compositions and uses thereof are provided. The antibodies and antibody conjugates, which may include a therapeutic agent or a diagnostic agent, may be used to treat, prevent or detect diseases such as for example cancer. ... 10/20/05 - 20050232923 - Methods and compositions for treating mcp-1 related pathologies The present invention relates to methods for treating at least one MCP-1 related condition or pathology, including therapeutic compositions, methods and devices. ... 10/13/05 - 20050226879 - Methods and compositions related to inhibiting nuclear envelope breakdown Disclosed are compositions and methods for inhibiting nuclear envelope breakdown. ... 10/06/05 - 20050220795 - Anti-hydroxylase antibodies and uses thereof Antibodies, or antigen-binding portions thereof, to aspartyl (asparaginyl) β-hydroxylase are provided. The anti-aspartyl (asparaginyl) β-hydroxylase antibodies, or antigen-binding portions thereof, can modulate activity of aspartyl (asparaginyl) β-hydroxylase. ... 09/22/05 - 20050208055 - Cytochrome p450 24 (cyp24) monoclonal antibody and methods and uses thereof This invention relates to a monoclonal antibody for CYP24 and to methods and uses therefore, such as in Western blot analysis, immunohistochemisty, protein purification; diagnostics, such as for cancer, vitamin D metabolic conditions and the like. ... 09/22/05 - 20050208054 - Methods of identifying insulin response modulators and uses therefor Methods of identifying insulin response modulators are provided. In particular, methods that feature identifying modulators of Akt and its associated substrates (including R-type calcium channel alpha-1E subunit (R-CaC1E), WNK1, FMS interacting protein (FMIP), nGAP-like protein, nuclear matrix protein p84, HIRA interacting protein 3 (HIRIP3), HSP71, ribosomal protein L6, guanine nucleotide ... 09/15/05 - 20050202016 - Purified sr-p70 protein The invention relates to new nucleic acid sequences of the family of tumour-suppressing genes related to the gene for the p53 protein, and to the corresponding protein sequences. ... 09/08/05 - 20050196399 - Prevention and treatment of amyloidogenic disease The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit. The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease. ... 09/08/05 - 20050196398 - Alzheimer's disease secretase, app substrates thereof, and uses thereof The present invention provides the enzyme and enzymatic procedures for cleaving the β secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cells and cell isolates and assays. An enzyme that cleaves the α-secretase site of APP also is provided. The invention further provides a modified ... 08/25/05 - 20050186211 - Use of mda-5 as an antiviral and antiproliferative agent The present invention relates to mda-5 nucleic acids, MDA-5 proteins, the mda-5 promoter, and related molecules, and the use of each of these elements in protecting against or limiting viral infection, controlling cell proliferation, and promoting apoptosis. It is based upon the discovery that, contrary to earlier hypotheses based on ... 08/25/05 - 20050186210 - Method for tissue regeneration The invention relates to DNA-sequences, their use and the use of DNA-sequences of the MAG gene or genes encoding the high mobility group proteins, agents for the treatment of various diseases including tumors, influencing the development of the vascular system, as well as for contraception and tissue regeneration, and appropriate ... 08/18/05 - 20050180977 - Endotheliase-2 ligands This disclosure provides, inter alia, proteins that bind to ET2, e.g., immunoglobulins that inhibit ET2 with high affinity and selectivity. The ET2 binding proteins can be used to treat a variety of disorders including angiogenesis-associated disorders. ... 08/11/05 - 20050175615 - Therapeutic vaccine targeted against p-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers The invention relates to an immunogenic composition which comprises, firstly, a carrier and, secondly, as antigenic structure, conjugates comprising all or part of the amino acid sequences of at least one peptide derived from an extracellular loop of the P-170 protein, each peptide being combined with several molecules of fatty ... 08/04/05 - 20050169927 - Human tissue factor antibodies The present invention relates to isolated fully human antibodies that immunoreacts with human tissue factor (TF) to inhibit the binding of coagulation factor VIIa (FVIIa). ... 08/04/05 - 20050169926 - Chimeric, human and humanized anti-csap monoclonal antibodies The present invention provides humanized, chimeric and human anti-CSAp antibodies and anti-CSAp antibody fusio proteins that are useful for the treatment and diagnosis of various cancers, including colon cancer. ... 08/04/05 - 20050169925 - Anti-amyloid beta antibodies and their use The present invention relates to antibody molecules capable of specifically recognizing two regions of the R-A4 peptide, wherein the first region comprises the amino acid sequence ABFRHDSGY as shown in SEQ ID NO: 1 or a fragment thereof and wherein the second region comprises the amino acid sequence VHHQKLVFFAEDVG as ... 07/28/05 - 20050163780 - Method for prolonged suppression of humoral immune response to a thymus-dependent antigen Methods of suppressing a humoral immune response to a thymus-dependent (TD) antigen are disclosed. The methods involve administering to a subject a TD antigen with an antagonist of a molecule which mediates contact-dependent helper effector functions. In a preferred embodiment, the antagonist is an antagonist of gp39. Primary and secondary ... 07/21/05 - 20050158321 - Treatment of rheumatoid arthritis with galectin-3 antagonists The invention encompasses a novel method of treating an inflammatory disease, such as rheumatoid arthritis, and novel methods of identifying and screening for drugs useful in the treatment of inflammatory diseases, such as rheumatoid arthritis, and their clinical symptoms. The inventors have made the discovery that the activity of galectin-3, ... 07/21/05 - 20050158320 - Combinations for the treatment of proliferative diseases The invention features combinations of drugs for the treatment of proliferative diseases (e.g., cancer). The invention also features methods for identifying new combination therapies for the treatment of cancer and other proliferative diseases. ... 07/07/05 - 20050147613 - Immunological control of beta-amyloid levels in vivo Disclosed are bispecific antibodies comprising a first antibody binding specificity which confers the ability of the bispecific antibody to cross the blood-brain barrier, and a second antibody specificity conferring the ability of the bispecific antibody to bind to a β-amyloid epitope. Also disclosed are methods for inhibiting the formation of ... 07/07/05 - 20050147612 - Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof Molecules comprising the antigen-binding portion of antibodies that block constitutive and/or ligand-dependent activation of a receptor protein tyrosine kinase, such as fibroblast growth factor receptor 3 (FGFR3), are found through screening methods, where a soluble dimeric form of a receptor protein tyrosine kinase is used as target for screening a ... 06/30/05 - 20050142137 - Antibodies against secretoryleukocyte protease inhibitor In accordance with the present invention, there are provided fully human monoclonal antibodies against secretory leukocyte protease inhibitor (SLPI) and antigen binding fragments thereof. Nucleotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules are provided. The invention provides antibodies and antigen-binding fragments thereof specifically bind ... 06/16/05 - 20050129695 - Anti-amyloid antibodies, compositions, methods and uses The present invention relates to at least one novel anti-amyloid antibody, including isolated nucleic acids that encode at least one anti-amyloid antibody, amyloid, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices. ... 06/16/05 - 20050129694 - Pharmaceutical composition for the prophylaxis and/or treatment of virus diseases The invention relates to the use of at least one active substance for producing a pharmaceutical composition for the prophylaxis and/or treatment of at least one viral disease. It is characterized by active substance(s) which inhibit(s) either at least two kinases or at least one SEK kinase of a cellular ... 06/09/05 - 20050123546 - Antigen binding molecules with increased fc receptor binding affinity and effector function The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human CD20. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such ... 06/09/05 - 20050123545 - Diagnosis and treatment of malignant neoplasms The invention features a method of inhibiting tumor growth and/or tumor invasiveness in a mammal by administering to a mammal a compound (e.g., an antagonistic antibody) which inhibits expression or enzymatic activity of human aspartyl (asparaginyl) beta-hydroxylase (HAAH). The invention also features a method for diagnosing the growth of a ... 06/09/05 - 20050123544 - Prevention and treatment of amyloidogenic disease The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit. The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease. ... 06/09/05 - 20050123543 - Ilk inhibitors for the treatment of renal disease The invention relates to the treatment of renal diseases using modulators of integrin linked kinase. Methods of treatment as well as therapeutic agents including antisense, small molecules, catalytic peptides and antibodies are disclosed. The agents of the invention may also be used in combination with traditional therapies for renal disease ... ### FreshPatents.com Support |